9 articles with Fountain Therapeutics
Fountain Therapeutics Congratulates Co-Founder and Executive Chairman Thomas Rando, M.D., Ph.D., for Prestigious NOMIS Distinguished Scientist Award
Fountain Therapeutics announced that Thomas Rando, M.D., Ph.D., co-founder and executive chairman of Fountain, is being honored in a ceremony held in Zurich to receive the prestigious NOMIS Distinguished Scientist Award.
BioSpace Movers & Shakers, Jan. 21
1/21/2022Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth.
Fountain Therapeutics Announces Appointment of Anupama Hoey as Chief Business Officer
Fountain Therapeutics today announced the appointment of Anupama Hoey as chief business officer (CBO) effective January 17 th , 2022.
Fountain Therapeutics Announces $15 Million Series A-2 Financing
Fountain Therapeutics today announced a $15 million Series A-2 financing, which brings its total Series A funding to $26 million.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
Fountain Therapeutics to Present at 2nd Annual LifeSci Partners Private Company Summer Symposium
Fountain Therapeutics today announced that William Greene, M.D., chief executive officer of Fountain, will present a corporate overview at the 2nd Annual LifeSci Partners Private Company Summer Symposium to be held July 21-23, 2021.
Fountain Therapeutics Appoints William L. Greene, M.D. Chief Executive Officer
Fountain Therapeutics, a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced the appointment of William L. Greene, M.D. as the company’s chief executive officer, effective April 26, 2021.
Fountain Therapeutics Moves Corporate Headquarters to Lilly Gateway Labs in South San Francisco
Fountain Therapeutics (“Fountain”), a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, today announced it has moved its corporate headquarters to Lilly Gateway Labs in South San Francisco upon selection by Eli Lilly and Company.
Fountain Therapeutics Closes $6 Million Series A-1 Financing
Closing brings total Series A financing sum to $11 million Funds to support expansion of team, technology platform and in vivo preclinical drug testing